Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

ESMO Open · 2025 · PMC12514499 · PMID 41033278

Europe PMC DOI

hedged sentences

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not reach statistical significanceP = 0.061so close (0.05 < p ≤ 0.1)

Median TILs were higher in non-responders (15%, IQR 5%-33.75%) than in responders (6.5%, IQR 1.24%-13.25%), though this difference did not reach statistical significance [OR = 0.929 (95% CI 0.846-0.988), P = 0.061] ( Figure 4 C).

also in 111,027 other papers

showed a trendno p-value reported

After adjusting for time since tissue collection, XBP1 ( P = 0.017), CD68 ( P = 0.020), and the PAM50 Proliferation Score ( P = 0.026) maintained significance, whereas CD79A ( P = 0.055) showed a trend toward statistical significance ( Supplementary Table S4 , available at https://doi.org/10.1016/j.esmoop.2025.105838 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.